Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2022 Nov 22;13:1091668. doi: 10.3389/fimmu.2022.1091668

Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions

Angela I Schriek 1, Marlies M van Haaren 1, Meliawati Poniman 1, Gillian Dekkers 2, Arthur E H Bentlage 3, Marloes Grobben 1, Gestur Vidarsson 3, Rogier W Sanders 1,4, Theo Verrips 5,6, Teunis B H Geijtenbeek 7, Raimond Heukers 2, Neeltje A Kootstra 7, Steven W de Taeye 1,*, Marit J van Gils 1,*
PMCID: PMC9723857  PMID: 36483568

In the published article, there was an error in the Funding statement. The funder was mentioned as AIDSfonds and Aids fonds instead of Aidsfonds. The correct Funding statement appears below.

Funding

This work was supported by HealthHolland/Aidsfonds: LSHM19101/P-44802, by HealthHolland/AMC: 2019-1167 and the AMC Fellowship from Amsterdam UMC received by MJG. ST is supported by Young investigator grant P-53301 Aidsfonds.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES